Abstract: The present application relates generally to methods for treating tumors, and in particular to methods for using peptides of both survivin and MAGE-A9 in dual-targeted immunotherapy that generates targeted T cell response against these two tumor antigens.

Abstract: The present application relates generally to methods for treating hematologic malignancy such as diffuse large B cell lymphoma (DLBCL), and in particular to methods involving detecting the expression of Programmed Death-Ligand 1 (PD-L1) in a biological sample of the subject and administering a T cell activation therapeutic with an inhibitor of PD-L1 or Programmed Death 1 (PD-1). It was surprisingly found that the level of PD-L1 expression correlates with the clinical responses with the T cell activation therapeutic together with an inhibitor of PD-L1 or PD-1 in the treatment of hematologic malignancies, thus, making PD-L1 an unexpected biomarker for the treatment of DLBCL.

Abstract: The present application relates generally to methods for treating tumors, and in particular to methods for improving the efficacy of a survivin therapeutic in the treatment of tumors by improving survivin specific T cell infiltration in tumor.